Loading live market data…

Antibe Therapeutics Inc.

TSX:ATE.TO

$0.295 CAD

$0.04 (13.46%)

Volume
167.04K
Average Volume
117.21K
Market Capitalization
$15.64M
P/E Ratio
-0.80
Dividend Yield
0.00%
Price Target
$
Year High
$1.23
Year Low
$0.15
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$15.03

Industry, Sector & symbol

Stock Exchange TSX
CEO Daniel Marcel Legault
Industry Medical - Devices
Sector Healthcare
Current Symbol ATE.TO
CUSIP None
CIK None
Web https://www.antibethera.com
Phone 416 922 3460
Currency CAD
Employees 11
Country CA

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 15.03
Quick Ratio 15.03
Cash Ratio 2.44

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -0.31
Price / Cash Flow -0.96
Price / Book 0.38

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating N/A
Rating Score(0-5) 0
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.37
Trailing P/E Ratio -0.80
PEG Ratio -0.05
P/E Growth -0.05
Net Income $-19.48M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity -40.16%
Return on Assets -27.60%

Financials Score

AltmanZ Score -3.88
Piotroski Score 1.00
Working Capital 25.3M
Total Assets 56.36M
Ebit -19.04M
Market Cap 15.64M
Total Liabilities 30.42M

Poll Results

About Antibe Therapeutics Inc. (TSX:ATE.TO) Stock

Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-35 ... 2, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.

Frequently Asked Questions

What is the current Antibe Therapeutics Inc. (ATE.TO) stock price?

Antibe Therapeutics Inc.(TSX:ATE.TO) stock price is $0.295 in the last trading session. During the trading session, ATE.TO stock reached the peak price of $1.23 while $0.15 was the lowest point it dropped to. The percentage change in ATE.TO stock occurred in the recent session was 13.46% while the dollar amount for the price change in ATE.TO stock was $0.04.

ATE.TO's industry and sector of operation?

The TSX listed ATE.TO is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of ATE.TO?

Ana Stegic | Executive Director of Clinical Operations
David James Vaughan | Chief Development Officer
Joseph Stauffer | Chief Medical Officer
Alain Wilson | Chief Financial Officer
Daniel Marcel Legault | President, Chief Executive Officer & Secretary

How many employees does ATE.TO have?

Number of ATE.TO employees currently stands at 11. ATE.TO operates from 15 Prince Arthur Avenue, Toronto, ON M5R 1B2, CA.

Link for ATE.TO official website?

Official Website of ATE.TO is: https://www.antibethera.com

How do I contact ATE.TO?

ATE.TO could be contacted at phone #416 922 3460 and can also be accessed through its website. ATE.TO operates from 15 Prince Arthur Avenue, Toronto, ON M5R 1B2, CA.

How many shares of ATE.TO are traded daily?

The average number of ATE.TO shares traded daily for last 3 months was 117.21K.

What is the market cap of ATE.TO currently?

The market value of ATE.TO currently stands at $15.64M with its latest stock price at $0.295